Literature DB >> 20172011

Incorporation of particle size differences between animal studies and human workplace aerosols for deriving exposure limit values.

Adriana R Oller1, Günter Oberdörster.   

Abstract

Inhalation animal studies usually employ homogeneous aerosols of small particle diameter. By contrast, workers are usually exposed to coarser and more heterogeneous aerosols. The particle size distribution of an aerosol will determine the deposited fraction of inhaled particles in the various regions of the respiratory tract in rodents and humans. The deposited, and subsequently retained, doses in these regions correlate closely with long-term toxic effects. Yet, differences in deposited doses between animals and humans due to particle size differences of aerosols have not been consistently taken into account in risk assessment. This paper describes an approach to calculate equivalent human concentrations (EHC) for respiratory tract effects after inhalation using workplace particle size information. Worker's exposure to the EHC results in the same deposited dose in the respiratory tract as achieved in animals exposed to the experimental particle size distribution. Example data for nickel compounds demonstrate that exposure levels used in the rat studies are equivalent to 4-11-fold higher levels of human workplace exposures. This approach is equally applicable to other metal/inorganic particulates that exert adverse effects on the respiratory tract after inhalation. Dosimetric extrapolation should be a first step in the derivation of limit values based on animal local respiratory effects. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20172011     DOI: 10.1016/j.yrtph.2010.02.006

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  7 in total

Review 1.  Is using nanosilver mattresses/pillows safe? A review of potential health implications of silver nanoparticles on human health.

Authors:  Sriram Prasath; Kavitha Palaniappan
Journal:  Environ Geochem Health       Date:  2019-01-22       Impact factor: 4.609

Review 2.  Elucidating the mechanisms of nickel compound uptake: a review of particulate and nano-nickel endocytosis and toxicity.

Authors:  Alexandra Muñoz; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2011-12-21       Impact factor: 4.219

3.  Incorporation of dosimetry in the derivation of reference concentrations for ambient or workplace air: a conceptual approach.

Authors:  Adriana R Oller; Günter Oberdörster
Journal:  J Aerosol Sci       Date:  2016-04-26       Impact factor: 3.433

4.  Exposure Assessment of Silver and Gold Nanoparticles Generated During the Synthesis Process in a South African Research Laboratory.

Authors:  Masilu D Masekameni; Charlene Andraos; Il Je Yu; Mary Gulumian
Journal:  Front Toxicol       Date:  2022-05-25

5.  Translational toxicology in setting occupational exposure limits for dusts and hazard classification - a critical evaluation of a recent approach to translate dust overload findings from rats to humans.

Authors:  Peter Morfeld; Joachim Bruch; Len Levy; Yufanyi Ngiewih; Ishrat Chaudhuri; Henry J Muranko; Ross Myerson; Robert J McCunney
Journal:  Part Fibre Toxicol       Date:  2015-04-23       Impact factor: 9.400

Review 6.  Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.

Authors:  Fernanda Pilaquinga; Jeroni Morey; Marbel Torres; Rachid Seqqat; María de Las Nieves Piña
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2021-02-27

7.  Response to the Reply on behalf of the 'Permanent Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area' (MAK Commission) by Andrea Hartwig Karlsruhe Institute of Technology (KIT).

Authors:  Peter Morfeld; Joachim Bruch; Len Levy; Yufanyi Ngiewih; Ishrat Chaudhuri; Henry J Muranko; Ross Myerson; Robert J McCunney
Journal:  Part Fibre Toxicol       Date:  2016-01-08       Impact factor: 9.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.